EPIIOS
DEAD

Serial Number

86797424

Owner

EPIIOS THERAPEUTICS GMBH

Attorney

Weitnauer Rechtsanwälte

Filing Date

Oct 23, 2015

Add to watchlist:

No watchlists yet
View on USPTO

EPIIOS Trademark

Serial Number: 86797424 • Registration: 5093926

EPIIOS is a trademark filed by EPIIOS THERAPEUTICS GMBH on October 23, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

EPIIOS THERAPEUTICS GMBH

ROBERT-KOCH-PLATZ
BERLIN 10115 , DE

Entity Type: 16

IC Discovery GmbH

Robert-Koch-Platz. 4
Berlin 10115 , DE

Entity Type: 16

Trademark Details

Filing Date

October 23, 2015

Registration Date

December 6, 2016

Published for Opposition

September 20, 2016

Cancellation Date

June 16, 2023

Goods & Services

Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, psychotropics; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient

Active chemical ingredients for use in the manufacture of anti-cancer drugs; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating human diseases of any kind; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for general industrial manufacturing; Chemical preparations, namely, silica based density centrifugation media, to be used in biochemical and clinical research; Chemicals for use in biotechnological product development; Chemicals for use in the biochemical and chemical industry; Chemicals, namely, buffer and standard solutions used in analytical chemistry; Industrial chemicals, namely, crosslinking coagents for thermoplastics; Reagents for use in scientific apparatus for chemical or biological analysis

Advanced product research in the field of artificial intelligence; Chemical, biochemical, biological and bacteriological research and analysis; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Consulting services in the field of medical physics; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Laboratory research services relating to pharmaceuticals; Medical research services in the field of cancer; Pharmaceutical research and development; Pharmaceutical research services; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of new products; Research and development of new products for others; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies

Filing History

CANCELLED SEC. 8 (6-YR)
Jun 16, 2023 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 6, 2021 REM1
REGISTERED-PRINCIPAL REGISTER
Dec 6, 2016 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 20, 2016 NPUB
PUBLISHED FOR OPPOSITION
Sep 20, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 31, 2016 NONP
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 24, 2016 ASGN
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 18, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 11, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 10, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 10, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 10, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 10, 2016 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 28, 2016 CRFA
ASSIGNED TO LIE
Jul 21, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 19, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 16, 2016 GNRN
NON-FINAL ACTION E-MAILED
Feb 16, 2016 GNRT
NON-FINAL ACTION WRITTEN
Feb 16, 2016 CNRT
ASSIGNED TO EXAMINER
Feb 16, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 28, 2015 NWOS
NEW APPLICATION ENTERED
Oct 27, 2015 NWAP